THOUSANDS of women suffering with breast cancer could benefit from a new pill.
Approved by the NHS, abemaciclib can cut the chance of the illness coming back once a tumour has been removed.
There are over 50,000 cases of the condition in women every year in the UK.
Breast cancer is the name given to any cancers that have first developed in the breast tissue – there are many different types.
Nearly 1,000 people die from the illness every month in the UK, with the disease killing around 11,500 women and 80 men each year.
The new twice-a-day pill, made by Eli Lilly is set to be given to over 4,000 women on the health service.
Read more on breast cancer
Medics said it’s suitable for women who are at high risk of recurrence and have had surgery.
These women have hormone receptor-positive, HER2-negative, node-positive early breast cancer.
It’s the most common type of the disease, accounting for around 70 per cent of all cases.
In early breast cancers, it’s estimated that it comes back after initial treatment in around 30 per cent of people.
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said: “It’s fantastic thousands of women with this type of primary breast cancer will now have an additional treatment option available on the NHS to help further reduce the risk of the disease coming back.
“The fear of breast cancer returning or spreading to other parts of their body and becoming incurable can cause considerable anxiety for so many women and their loved ones.
“New effective treatments such as abemaciclib, which can offer more women the chance to further reduce the risk of the disease recurring, are therefore extremely welcome and this is an important step-change in the drug options available for this group of patients.”
